Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, et al. Gastroenterology 2022;162:495-508.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, et al. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology 2022;162:495-508.
PMID: 34748774